224 research outputs found
An Infinite Needle in a Finite Haystack: Finding Infinite Counter-Models in Deductive Verification
First-order logic, and quantifiers in particular, are widely used in
deductive verification. Quantifiers are essential for describing systems with
unbounded domains, but prove difficult for automated solvers. Significant
effort has been dedicated to finding quantifier instantiations that establish
unsatisfiability, thus ensuring validity of a system's verification conditions.
However, in many cases the formulas are satisfiable: this is often the case in
intermediate steps of the verification process. For such cases, existing tools
are limited to finding finite models as counterexamples. Yet, some quantified
formulas are satisfiable but only have infinite models. Such infinite
counter-models are especially typical when first-order logic is used to
approximate inductive definitions such as linked lists or the natural numbers.
The inability of solvers to find infinite models makes them diverge in these
cases. In this paper, we tackle the problem of finding such infinite models.
These models allow the user to identify and fix bugs in the modeling of the
system and its properties. Our approach consists of three parts. First, we
introduce symbolic structures as a way to represent certain infinite models.
Second, we describe an effective model finding procedure that symbolically
explores a given family of symbolic structures. Finally, we identify a new
decidable fragment of first-order logic that extends and subsumes the
many-sorted variant of EPR, where satisfiable formulas always have a model
representable by a symbolic structure within a known family. We evaluate our
approach on examples from the domains of distributed consensus protocols and of
heap-manipulating programs. Our implementation quickly finds infinite
counter-models that demonstrate the source of verification failures in a simple
way, while SMT solvers and theorem provers such as Z3, cvc5, and Vampire
diverge
Oral Mucositis
Mucositis is a generalized term used to denote either oral or gastrointestinal mucositis as a consequence of cancer therapy. This chapter will describe the epidemiology of mucositis in relation to radiation therapy for head and neck cancers, chemotherapy, and hematopoietic stem cell transplantation. Clinical features, risk factors and pathogenesis of mucositis are covered in depth. In addition, the current consensus on mucositis management and economic consequences are reviewed in this chapter. Although considered to have a different pathogenesis, targeted therapy related oral mucosal adverse effects are often referred in the literature as mucositis or stomatitis. This entity is described in this chapter, too.</p
Recommended from our members
Intravitreal Administration of Human Bone Marrow CD34+ Stem Cells in a Murine Model of Retinal Degeneration.
PurposeIntravitreal murine lineage-negative bone marrow (BM) hematopoietic cells slow down retinal degeneration. Because human BM CD34+ hematopoietic cells are not precisely comparable to murine cells, this study examined the effect of intravitreal human BM CD34+ cells on the degenerating retina using a murine model.MethodsC3H/HeJrd1/rd1 mice, immunosuppressed systemically with tacrolimus and rapamycin, were injected intravitreally with PBS (n = 16) or CD34+ cells (n = 16) isolated from human BM using a magnetic cell sorter and labeled with enhanced green fluorescent protein (EGFP). After 1 and 4 weeks, the injected eyes were imaged with scanning laser ophthalmoscopy (SLO)/optical coherence tomography (OCT) and tested with electroretinography (ERG). Eyes were harvested after euthanasia for immunohistochemical and microarray analysis of the retina.ResultsIn vivo SLO fundus imaging visualized EGFP-labeled cells within the eyes following intravitreal injection. Simultaneous OCT analysis localized the EGFP-labeled cells on the retinal surface resulting in a saw-toothed appearance. Immunohistochemical analysis of the retina identified EGFP-labeled cells on the retinal surface and adjacent to ganglion cells. Electroretinography testing showed a flat signal both at 1 and 4 weeks following injection in all eyes. Microarray analysis of the retina following cell injection showed altered expression of more than 300 mouse genes, predominantly those regulating photoreceptor function and maintenance and apoptosis.ConclusionsIntravitreal human BM CD34+ cells rapidly home to the degenerating retinal surface. Although a functional benefit of this cell therapy was not seen on ERG in this rapidly progressive retinal degeneration model, molecular changes in the retina associated with CD34+ cell therapy suggest potential trophic regenerative effects that warrant further exploration
Systematic Review of Laser and Other Light Therapy for the Management of Oral Mucositis in Cancer Patients
Background The aim of this study was to review the available literature and define clinical practice guidelines for the use of laser and other light therapies for the prevention and treatment of oral mucositis.
Methods A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based onthe evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, and no guideline possible.
Results A new recommendation was made for low-level laser (wavelength at 650 nm, power of 40 mW, and each square centimeter treated with the required time to a tissue energy dose of 2 J/cm2 (2 s/point)) for the prevention of oral mucositis in adult patients receiving hematopoietic stem cell transplantation conditioned with high-dose chemotherapy, with or without total body irradiation. A new suggestion was made for low-level laser (wavelength around 632.8 nm) for the prevention of oral mucositis in patients undergoing radiotherapy, without concomitant chemotherapy, for head and neck cancer. No guideline was possible in other populations and for other light sources due to insufficient evidence.
Conclusions The increasing evidence in favor of low-level laser therapy allowed for the development of two new guidelines supporting this modality in the populations listed above. Evidence for other populations was also generally encouraging over a range of wavelengths and intensities. However, additional well-designed research is needed to evaluate the efficacy of laser and other light therapies in various cancer treatment settings
Safety and efficacy of an intra-oral electrostimulator for the relief of dry mouth in patients with chronic graft versus host disease: case Series
Objectives: Patients with chronic graft-versus-host disease (cGVHD) often suffer from dry mouth and oral mu
-
cosal lesions. The primary objective of this study was to investigate the safety of an intra-oral electrostimulator
(GenNarino) in symptomatic cGVHD patients. The secondary objective was to study the impact on the salivary
gland involvement of cGVHD patients.
Study Design: This paper presents a case series. The study included patients treated for 4 weeks, randomly as
-
signed to the active device and then crossed-over to a sham-device or vice versa. The patients and clinicians were
blind to the treatment delivered. Data regarding oral mucosal and salivary gland involvement were collected.
Results: Six patients were included in this series. Most of the intraoral areas with manifestations of cGVHD were
not in contact with the GenNarino device. Two patients developed mild mucosal lesions in areas in contact with
the GenNarino during the study. However, only one of them had a change in the National Institutes of Health
(NIH) score for oral cGVHD. The unstimulated and stimulated salivary flow rate increased in 4 out of the 5 pa
-
tients included in this analysis. Symptoms of dry mouth and general oral comfort improved.
Conclusion: This study suggests that GenNarino is safe in cGVHD patients with respect to oral tissues. Furthermore
the use of GenNarino resulted in subjective and objective improvements in dry mouth symptoms. A large scale study
is needed to confirm the impact and safety of GenNarino on systemic cGVHD
Recommended from our members
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.
In recent years oral mucosal injury has been increasingly recognized as an important toxicity associated with mammalian target of rapamycin (mTOR) inhibitors, including in patients with breast cancer who are receiving everolimus. This review addresses the state-of-the-science regarding mTOR inhibitor-associated stomatitis (mIAS), and delineates its clinical characteristics and management. Given the clinically impactful pain associated with mIAS, this review also specifically highlights new research focusing on the study of the molecular basis of pain. The incidence of mIAS varies widely (2-78%). As reported across multiple mTOR inhibitor clinical trials, grade 3/4 toxicity occurs in up to 9% of patients. Managing mTOR-associated oral lesions with topical oral, intralesional, and/or systemic steroids can be beneficial, in contrast to the lack of evidence supporting steroid treatment of oral mucositis caused by high-dose chemotherapy or radiation. However, steroid management is not uniformly efficacious in all patients receiving mTOR inhibitors. Furthermore, technology does not presently exist to permit clinicians to predict a priori which of their patients will develop these lesions. There thus remains a strategic need to define the pathobiology of mIAS, the molecular basis of pain, and risk prediction relative to development of the clinical lesion. This knowledge could lead to novel future interventions designed to more effectively prevent mIAS and improve pain management if clinically significant mIAS lesions develop
Clinical use of photobiomodulation for the prevention and treatment of oral mucositis: the real-life experience of MASCC/ISOO members
AimTo assess clinical use and patient outcome of photobiomodulation (PBM) for oral mucositis (OM) prevention and treatment among specialized practitioners.MethodsA poll was emailed to the members of the Mucositis Study Group of MASCC/ISOO. The PBM parameters used by the respondents were analyzed using exploratory statistical methods to identify combinations of PBM parameters (patterns) that characterize the variance in the protocols (principal component analysis).ResultsResponses were received from 101 MSG members, with 78 providing analyzable data. Most of the responders were dental practitioners or oral medicine specialists. PBM was used by 59% of the responders for OM or targeted therapy stomatitis. Technical parameters varied widely. Most responders used wavelengths & SIM;650 nm intra-orally. The spot-size and distance from the tissue were the main factors driving the variation. All PBM users noted that PBM relieved pain, either immediately or a delayed effect. High likelihood of pain relief (measured as responder's report of pain relief in 67-100% of patients) was reported by 22% and 19% of PBM users for immediate pain relief and delayed pain relief, respectively. The most common reported barriers to using PBM were financial considerations, time constraints, lack of training or experience and concern about the potential for malignant transformation or increased risk of cancer recurrence.ConclusionsThe use of PBM for OM prevention or treatment is in early phases of adoption in practices, facing some obstacles to implement it. A wide variation in technical parameters was found. Nonetheless, responses indicate that PBM provided pain relief
Recommended from our members
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).Patients and methodsWe performed a prospective, open-label, multicenter phase II clinical trial of ipilimumab plus nivolumab across multiple rare tumor cohorts, with the (nonpancreatic) neuroendocrine cohort reported here. Response assessment by grade was not prespecified. The primary endpoint was overall response rate [ORR; RECIST v1.1; complete response (CR) and partial response (PR)]; secondary endpoints included progression-free survival (PFS), overall survival (OS), stable disease >6 months, and toxicity.ResultsThirty-two eligible patients received therapy; 18 (56%) had high-grade disease. Most common primary sites were gastrointestinal (47%; N = 15) and lung (19%; N = 6). The overall ORR was 25% [95% confidence interval (CI) 13-64%; CR, 3%, N = 1; PR, 22%, N = 7]. Patients with high-grade neuroendocrine carcinoma had an ORR of 44% (8/18 patients) versus 0% in low/intermediate grade tumors (0/14 patients; P = 0.004). The 6-month PFS was 31% (95% CI, 19%-52%); median OS was 11 months (95% CI, 6-∞). The most common toxicities were hypothyroidism (31%), fatigue (28%), and nausea (28%), with alanine aminotransferase elevation (9%) as the most common grade 3/4 immune-related adverse event, and no grade 5 events.ConclusionsIpilimumab plus nivolumab demonstrated a 44% ORR in patients with nonpancreatic high-grade neuroendocrine carcinoma, with 0% ORR in low/intermediate grade disease
- …